There was a 29 % reduction in the number of recurrences occurring within the trial ( IRR : 0.71 95 % CI : 0.53 to 0.90 , p = 0.02 ) , corresponding to an absolute reduction of recurrence of 0.31 recurrences/patient ( 95 % CI : 0.05 to 0.59 , p = 0.02 ) .